HMG-CoA Reductase Inhibitor for postmenopausal patients used as Arterial stiffness (ASI) index ; A Phase II randomized controlled study

HMG-CoA Reductase Inhibitor for postmenopausal patients used as Arterial stiffness (ASI) index ; A Phase II randomized controlled study - HMG-CoA Reductase Inhibitor for postmenopausal patients used as ASI index

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025555

Enrollment

Registered

2017-01-06

Start date

2013-05-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postmenopausal women (70&gt

Interventions

kinesitherapy and deiotherapy are based on third Report of the National Cholesterol Education Program (NCEP) for 1 year. Pravastatin (10mg/day) is administered for 1 year.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Postmenopausal women with hypercholesterolemia (LDL>=140mg/dl)

Exclusion criteria

Exclusion criteria: 1.familial hypercholesterolemia 2.allergy to Pravastatin 3.pregnant woman 4.hypertension 5.angina pectoris or myocardial infarction 6.stroke 7.Atrial fibrillation 8.Rheumatism 9.hepatitis or Cirrhosis of the liver 10.cancer patient

Design outcomes

Primary

Measure	Time frame
the rate of change of ASI 1 year later after treatment	—

Secondary

Measure	Time frame
the rate of change of TCHO, LDL and HDL value 1 year later after treatment	—

Countries

Japan

Contacts

Public ContactRyuji Kawaguchi

Nara Medical University Obstetrics and Gynecology

kawaryu@naramed-u.ac.jp0744-22-3051

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026